Inloggen
E-mail
Wachtwoord
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON
  1. Homepagina
  2. Aandelen
  3. BelgiŽ
  4. Euronext Bruxelles
  5. Argenx SE
  6. Nieuws
  7. Persberichten
    ARGX   NL0010832176

ARGENX SE

(ARGX)
Real-time koersen. Real Time Euronext Bruxelles - 23/07 17:35:00
267.9 EUR   -1.33%
19/07KBC Securities zet Argen-x op de kooplijst
AM
14/07Argen-x houdt R&D dag op 20 juli
AM
18/06ARGENX SE : UBS herhaalt koopadvies voor het aandeel
MM
OverzichtKoersenGrafiekenNieuwsRatingenAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuwsAnalyse MarketScreener
Communiquťs de presse de la sociťtť ARGENX SE
22/07ARGENX : argenx to Report Half Year 2021 Financial Results and Second Quarter Bu..
PU
22/07argenx to Report Half Year 2021 Financial Results and Second Quarter Business..
GL
22/07ARGENX : to Report Half Year 2021 Financial Results and Second Quarter Business ..
AQ
14/07ARGENX : argenx to Host Virtual R&D Day on July 20, 2021
PU
14/07ARGENX : to Host Virtual R&D Day on July 20, 2021
AQ
17/06argenx announces publication of Phase 3 ADAPT trial results of efgartigimod f..
GL
07/06ARGENX : to regain global rights to cusatuzumab (Form 6-K)
PU
07/06argenx to regain global rights to cusatuzumab
GL
01/06ARGENX : Appoints Karl Gubitz as Chief Financial Officer (Form 6-K)
PU
01/06argenx Appoints Karl Gubitz as Chief Financial Officer
GL
01/06ARGENX : to Present at Upcoming Investor Conferences
AQ
14/05argenx Reports First Quarter 2021 Financial Results and Provides Business Upd..
GL
11/05argenx announces results of Annual General Meeting of Shareholders
GL
11/05ARGENX : announces results of Annual General Meeting of Shareholders (Form 6-K)
PU
07/05argenx to Report First Quarter 2021 Financial Results and Business Update on ..
GL
28/04argenx Management to Present at Upcoming Virtual Investor Conferences
GL
30/03argenx announces Annual General Meeting of Shareholders on May 11, 2021
GL
04/03argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter B..
GL
02/03argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatm..
GL
25/02ARGENX : to Report Full Year 2020 Financial Results and Fourth Quarter Business ..
AQ
08/02BROADRIDGE FINANCIAL : argenx announces closing of global offering
AQ
05/02argenx announces closing of global offering
GL
05/02ARGENX : announces full exercise of underwriters option to purchase additional A..
AQ
04/02argenx announces full exercise of underwriters' option to purchase additional..
GL
03/02argenx raises $1.0 billion in gross proceeds in a global offering
GL
02/02ARGENX : Issues Statement Concerning Efgartigimod
AQ
02/02argenx Issues Statement Concerning Efgartigimod
GL
01/02argenx announces launch of proposed global offering
GL
01/02“GO” DECISION : ADHERE Trial in CIDP
PU
01/02argenx Announces “GO” Decision in ADHERE Trial of Efgartigimod in..
GL
08/01ARGENX : Announces 2021 Corporate Priorities and Highlights Recent Achievements ..
AQ
05/01ARGENX : to Present at 39th Annual J.P. Morgan Healthcare Conference
AQ
04/01argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
GL
2020ARGENX : Enters Into Agreement To Acquire Priority Review Voucher
AQ
2020argenx Enters Into Agreement To Acquire Priority Review Voucher
GL
2020ARGENX : to Participate in Upcoming Virtual Investor Conferences
AQ
2020argenx to Participate in Upcoming Virtual Investor Conferences
GL
2020ARGENX : Q3 FY20 Earnings conference call and audio webcast
PU
2020ARGENX : Reports Third Quarter 2020 Financial Results and Provides Business Upda..
AQ
2020argenx Reports Third Quarter 2020 Financial Results and Provides Business Upd..
GL
2020ARGENX : to Report Third Quarter 2020 Financial Results and Business Update on O..
AQ
2020ARGENX : to Report Third Quarter 2020 Financial Results and Business Update on O..
AQ
2020argenx to Report Third Quarter 2020 Financial Results and Business Update on ..
GL
2020ARGENX : Expands Capabilities In Antibody Engineering Through Key Technology Par..
AQ
2020argenx Expands Capabilities In Antibody Engineering Through Key Technology Pa..
GL
2020ARGENX : Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial a..
AQ
2020argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial ..
GL
2020ARGENX : MGFA 2020 Virtual Scientific Session
PU
2020argenx Management to Present at Upcoming Virtual Investor Conferences
GL
2020argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
GL
2020ARGENX : Half year 2020 financial results and second quarter business update on ..
PU
2020argenx reports half year 2020 financial results and provides second quarter b..
GL
2020ARGENX : Announces Positive Topline Phase 3 ADAPT Trial Results
PU
2020ARGENX : Positive Topline Phase 3 ADAPT Trial Results
PU
2020ARGENX : Securities Note
PU
2020argenx announces closing of global offering
GL
2020argenx announces full exercise of underwriters' option to purchase additional..
GL
2020argenx raises $750 million in gross proceeds in a global offering
GL
2020argenx announces launch of proposed global offering
GL
2020argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgarti..
GL
2020argenx reports first quarter 2020 financial results and provides business upd..
GL
2020ARGENX : announces results of Annual General Meeting of Shareholders
AQ
2020ARGENX : to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020..
AQ
2020ARGENX : to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020..
PU
2020ARGENX : to report first quarter 2020 financial results and business update on M..
PU
2020ARGENX : to Present at BofA Securities Virtual Health Care Conference 2020
PU
2020ARGENX : 2020 AGM Explanatory notes
PU
2020ARGENX : 2020 AGM Concovation notice
PU
2020ARGENX : Proposed new 2020 Remuneration Policy vAGM
PU
2020ARGENX : 2020 AGM Agenda
PU
2020ARGENX : announces Annual General Meeting of Shareholders on May 12, 2020
PU
2020ARGENX : Full year 2019 financial results and provides fourth quarter business u..
PU
2020argenx reports full year 2019 financial results and provides fourth quarter b..
GL
2020ARGENX : to Present at Cowen 40th Annual Health Care Conference
PU
2020ARGENX : to report full year 2019 financial results and fourth quarter business ..
PU
1  2  3  4  5Volgende
Volgende evenement op ARGENX SE
29/07/21